Showing 2111-2120 of 2657 results for "".
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Celanese Announces a Research Agreement with Johns Hopkins University to Advance Sustained Ocular Drug Delivery to the Suprachoroidal Spacehttps://modernod.com/news/celanese-announces-a-research-agreement-with-johns-hopkins-university-to-advance-sustained-ocular-drug-delivery-to-the-suprachoroidal-space/2481417/Specialty materials and chemical company Celanese announced an agreement with Johns Hopkins University Department of Ophthalmology to collaborate on a study of sustained drug delivery to the suprachoroidal space in the eye. A bioinert implant based on the Celanese's VitalD
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C
- Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/frontera-therapeutics-doses-first-patient-in-a-trial-of-ft-002-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa/2481415/Frontera Therapeutics announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002, which is being studied for the treatment of X-linked retinitis pigmentosa (XLRP) and is Frontera’s third gene therapy product candidate to enter the clinic.
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- Harrow Launches Next-Generation Compounded Atropine Formulationshttps://modernod.com/news/harrow-launches-next-generation-compounded-atropine-formulations/2481410/Harrow announced the launch of its patent-pending, next-generation compounded atropine formulations. The formulations are now available through Harrow’s wholly owned compounding and mail order pharmacy subsidiary, ImprimisRx. According to Harrow, the ImprimisRx
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis for Wet AMD Meets Primary Endpointhttps://modernod.com/news/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-meets-primary-endpoint/2481405/Opthea announced that the phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), met the prespecified primary efficacy endpoint.
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat
- Alcon Canada Launches TOTAL Toric Lenses for Astigmatic Patientshttps://modernod.com/news/alcon-canada-launches-total-toric-lenses-for-astigmatic-patients/2481383/Alcon announced the Canadian launch of Total30 for Astigmatism and Dalies Total1 for Astigmatism, extending Alcon’s portfolio of reusable and daily disposable lenses for astigmatic patients. Estimates show that toric lenses is the fastest growing